Amarin Corporation plc (AMRN) CEO Pat Holt presents at 42nd Annual J.P. Morgan Healthcare Conference (Transcript)
https://seekingalpha.com/article/4662245-amarin-corporation-plc-amrn-ceo-pat-holt-presents-42nd-annual-j-p-morgan-healthcare?source=feed_sector_transcripts
Jan 10, 2024 - Amarin Corporation plc (NASDAQ:NASDAQ:AMRN) 42nd Annual J.P.
0
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/29/amarin-plc-amrn-q4-2023-earnings-call-transcript/?source=iedfolrf0000001
Feb 29, 2024 - AMRN earnings call for the period ending December 31, 2023.
0
What Makes Amarin (AMRN) a New Buy Stock
https://www.zacks.com/stock/news/2193741/what-makes-amarin-amrn-a-new-buy-stock?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_12_zacks_rank_upgrade-2193741
Dec 05, 2023 - Amarin (AMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
0
Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?
https://www.zacks.com/stock/news/2228685/can-low-occupancy-rate-affect-select-medical-sem-q4-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-2228685
Feb 20, 2024 - Select Medical's (SEM) fourth-quarter results are likely to reflect growing visits in Outpatient Rehabilitation and Concentra.
0
Are Medical Stocks Lagging Amarin (AMRN) This Year?
https://www.zacks.com/stock/news/2209522/are-medical-stocks-lagging-amarin-amrn-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2209522
Jan 12, 2024 - Here is how Amarin (AMRN) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
0
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
https://www.zacks.com/stock/news/2250719/amarin-amrn-up-7-on-intellectual-property-wins-in-europe?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250719
Apr 04, 2024 - Amarin (AMRN) secures a new patent for Vazkepa in Europe, which extends its exclusivity for eight more years. It achieves success in defending another patent on the drug against third parties.
0
Pages: 1
Page 1